A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone

Cancer Research

Volumn 65, Issue 20, 2005, Pages 9426-9435

  Halvorson, Kyle G ^a   Kubota, Kazufumi ^a   Sevcik, Molly A ^a   Lindsay, Theodore H ^a   Sotillo, Julio E ^a   Ghilardi, Joseph R ^a,b   Rosol, Thomas J ^c   Boustany, Leila ^d   Shelton, David L ^d   Mantyh, Patrick W ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d Rinat Neuroscience Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE SULFATE; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY; PENTOBARBITAL; PROTEIN P75; PROTEIN TYROSINE KINASE A;

ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE METASTASIS; BONE PAIN; CANCER MODEL; CANCER PAIN; CONTROLLED STUDY; DRUG EFFICACY; FEMUR; MALE; MOUSE; NERVE FIBER TRANSPORT; NEUROPATHIC PAIN; NOCICEPTIVE RECEPTOR; NONHUMAN; NUDE MOUSE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SENSORY NERVE; SYMPATHETIC INNERVATION; TUMOR GROWTH;

ANALGESICS, OPIOID; ANIMALS; ANTIBODIES; BONE AND BONES; BONE NEOPLASMS; BONE REMODELING; BRAIN; CELL LINE, TUMOR; DISEASE PROGRESSION; DOGS; MALE; MICE; MICE, NUDE; MORPHINE; NERVE GROWTH FACTOR; PAIN; PROSTATIC NEOPLASMS; RNA, MESSENGER; SKIN;

EID: 27144433512     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0826     Document Type: Article

References (59)

1. Olson KB, Pienta KJ. Pain management in patients with advanced prostate cancer [discussion 49-50 passim]. Oncology 1999;13:1537-49.
2. Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 1998;24:425-32.
3. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81.
4. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997;69:1-18.
5. Portenoy RK. Managing cancer pain poorly responsive to systemic opioid therapy. Oncology 1999;13:25-9.
6. Body JJ. Tumor bone diseases and osteoporosis in cancer patients. 1st ed. New York: Marcel Dekker, Inc.; 2000. p. 561.
7. Shu XQ, Mendell LM. Neurotrophins and hyperalgesia. Proc Natl Acad Sci U S A 1999;96:7693-6.
8. Koltzenburg M. The changing sensitivity in the life of the nociceptor. Pain 1999;Suppl 6:S93-102.
9. Andreev NY, Dmitrieva N, Koltzenburg M, McMahon SB. Peripheral administration of nerve growth factor in the adult rat produces a thermal hyperalgesia that requires the presence of sympathetic post-ganglionic neurones. Pain 1995;63:109-15.
10. Mendell LM, Albers KM, Davis BM. Neurotrophins, nociceptors, and pain. Microsc Res Tech 1999;45:252-61.
11. Susaki Y, Shimizu S, Katakura K, et al. Functional properties of murine macrophages promoted by nerve growth factor. Blood 1996;88:4630-7.
12. Lewin GR, Rueff A, Mendell LM. Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur J Neurosci 1994;6:1903-12.
13. Descamps S, Toillon RA, Adriaenssens E, et al. Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J Biol Chem 2001;276:17864-70.
14. Sevcik MA, Ghilardi JR, Peters CM, et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 2005;115:128-41.
15. Hongo JS, Laramee GR, Urfer R, et al. Antibody binding regions on human nerve growth factor identified by homolog- and alanine-scanning mutagenesis. Hybridoma 2000;19:215-27.
16. Shelton DL, Zeller J, Ho W-H, Pons J, Rosenthal A. Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. Pain 2005;116:8-16.
17. McCarthy BG, Hsieh ST, Stocks A, et al. Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology 1995;45:1848-55.
18. Corey E, Quinn JE, Bladou F, et al. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 2002;52:20-33.
19. Fawcett DW. A Textbook of Histology. In: Dreibelbis D, editor. Bone, 11th ed. Philadelphia (PA): W.B. Saunders Company: 1986. p. 211-3.
20. Sevcik MA, Luger NM, Mach DB, et al. Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. Pain 2004;111:169-80.
21. Mach DB, Rogers SD, Sabino MC, et al. Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience 2002;113:155-66.
22. Luger NM, Honore P, Sabino MA, et al. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 2001;61:4038-47.
23. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994;53:55-63.
24. Berruti A, Dogliotti L, Bitossi R, et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000;164:1248-53.
25. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005;5:21-8.
26. LeRoy BE, Bahnson RR, Rosol TJ. Canine prostate induces new bone formation in mouse calvaria: a model of osteoinduction by prostate tissue. Prostate 2002;50:104-11.
27. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-94.
28. Clohisy DR, Mantyh PW. Bone cancer pain. Cancer 2003;97:866-73.
29. Walsh TD. Prevention of opioid side effects. J Pain Symptom Manage 1990;5:362-7.
30. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
31. Davies NM, Jamali F. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J Pharm Pharm Sci 2004;7:332-6.
32. Mercadante S. Problems of long-term spinal opioid treatment in advanced cancer patients. Pain 1999;79:1-13.
33. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
34. Guise TA, Chirgwin JM. Role of bisphosphonates in prostate cancer bone metastases. Semin Oncol 2003;30:717-23.
35. Schwei MJ, Honore P, Rogers SD, et al. Neurochemical and cellular reorganization of the spinal cord in a marine model of bone cancer pain. J Neurosci 1999;19:10886-97.
36. Medhurst SJ, Walker K, Bowes M, et al. A rat model of bone cancer pain. Pain 2002;96:129-40.
37. Revilla M, Arribas I, Sanchez-Chapado M, Villa LF, Bethencourt F, Rico H. Total and regional bone mass and biochemical markers of bone remodeling in metastatic prostate cancer. Prostate 1998;35:243-7.
38. Adler CP. Bone diseases: macroscopic, histological, and radiological diagnosis of structural changes in the skeleton. 2nd ed. Berlin: Springer-Verlag; 2000.
39. Schwei MJ, Honore P, Rogers SD, et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 1999;19:10886-97.
40. Rueff A, Dawson AJ, Mendell LM. Characteristics of nerve growth factor induced hyperalgesia in adult rats: dependence on enhanced bradykinin-1 receptor activity but not neurokinin-1 receptor activation. Pain 1996;66:359-72.
41. Verge VM, Tetzlaff W, Bisby MA, Richardson PM. Influence of nerve growth factor on neurofilament gene expression in mature primary sensory neurons. J Neurosci 1990;10:2018-25.
42. Averill S, Michael GJ, Shortland PJ, et al. NGF and GDNF ameliorate the increase in ATF3 expression which occurs in dorsal root ganglion cells in response to peripheral nerve injury. Eur J Neurosci 2004;19:1437-45.
43. Donnerer J, Schuligoi R, Stein C. Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: evidence for a regulatory function of nerve growth factor in vivo. Neuroscience 1992;49:693-8.
44. Gould HJ III, Gould TN, England JD, Paul D, Liu ZP, Levinson SR. A possible role for nerve growth factor in the augmentation of sodium channels in models of chronic pain. Brain Res 2000;854:19-29.
45. Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002;36:57-68.
46. Ramer MS, Bradbury EJ, McMahon SB. Nerve growth factor induces P2X(3) expression in sensory neurons. J Neurochem 2001;77:864-75.
47. Mamet J, Lazdunski M, Voilley N. How nerve growth factor drives physiological and inflammatory expressions of acid-sensing ion channel 3 in sensory neurons. J Biol Chem 2003;278:48907-13.
48. Heumann R, Korsching S, Bandtlow C, Thoenen H. Changes of nerve growth factor synthesis in non-neuronal cells in response to sciatic nerve transection. J Cell Biol 1987;104:1623-31.
49. Zahn PK, Subieta A, Park SS, Brennan TJ. Effect of blockade of nerve growth factor and tumor necrosis factor on pain behaviors after plantar incision. J Pain 2004;5:157-63.
50. Averill S, McMahon SB, Clary DO, Reichardt LF, Priestley JV. Immunocytochemical localization of trkA receptors in chemically identified subgroups of adult rat sensory neurons. Eur J Neurosci 1995;7:1484-94.
51. Walsh GS, Krol KM, Kawaja MD. Absence of the p75 neurotrophin receptor alters the pattern of sympathosensory sprouting in the trigeminal ganglia of mice overexpressing nerve growth factor. J Neurosci 1999;19:258-73.
52. Bjurholm A, Kreicbergs A, Brodin E, Schultzberg M. Substance P- and CGRP-immunoreactive nerves in bone. Peptides 1988;9:165-71.
53. Foster PA, Wicks S, Foster M, Brain SD. Cellular pathology changes in rat skin following intradermal injection of nerve growth factor: neutrophil-dependent and -independent events. J Pathol 2002;197:245-55.
54. Bergmann I, Reiter R, Toyka KV, Koltzenburg M. Nerve growth factor evokes hyperalgesia in mice lacking the low-affinity neurotrophin receptor p75. Neurosci Lett 1998;355:87-90.
55. Petersen M, Segond von Banchet G, Heppelmann B, Koltzenburg M. Nerve growth factor regulates the expression of bradykinin binding sites on adult sensory neurons via the neurotrophin receptor p75. Neuroscience 1998;83:161-8.
56. Tokunaga J. The innervation of the diaphysis of the cat tibia. J Anat 1967;101:125-36.
57. Seike W. Electrophysiological and histological studies on the sensibility of the bone marrow nerve terminal. Yonago Acta Med 1976;20:192-211.
58. Cornelissen BP, Buma P, Rijkenhuizen AB, Barneveld A. Innervation of the equine mature and immature proximal sesamoid bone by calcitonin gene-related peptide and substance P-containing nerves. Am J Vet Res 1998;59:1378-85.
59. Gronblad M, Liesi P, Korkala O, Karaharju E, Polak J. Innervation of human bone periosteum by peptidergic nerves. Anat Rec 1984;209:297-9.